^abcdFlores-Murrieta FJ, Hong E, Castañeda-Hernández G (June 1988). "Sensitive high-performance liquid chromatographic assay of pelanserin, a novel antihypertensive agent, in plasma samples".Journal of Chromatography.428 (1):167–172.doi:10.1016/s0378-4347(00)83903-1.PMID3170670.
^ab"Pelanserin".AdisInsight. 30 August 2002. Retrieved17 January 2026.
^Villalobos-Molina R, Ibarra M, Hong E (April 1995). "The 5-HT2 receptor antagonist, pelanserin, inhibits alpha 1-adrenoceptor-mediated vasoconstriction in vitro".European Journal of Pharmacology.277 (2–3):181–185.doi:10.1016/0014-2999(95)00074-u.PMID7493607.
^abFlores-Murrieta FJ, Herrera JE, Castañeda-Hernández G, Hong E (1992). "Pharmacokinetics of pelanserin in healthy volunteers".Proceedings of the Western Pharmacology Society.35:113–116.PMID1502209.
^Espinoza R, Hong E, Villafuerte L (May 2000). "Influence of admixed citric acid on the release profile of pelanserin hydrochloride from HPMC matrix tablets".International Journal of Pharmaceutics.201 (2):165–173.doi:10.1016/s0378-5173(00)00406-3.PMID10878323.Pelanserin is a weakly basic experimental drug with a short half-life and a prolonged release formulation was developed using hydroxypropyl methylcellulose (HPMC) and citric acid to set up a system bringing about gradual release of this drug.
^Hayao S, Havera HJ, Strycker WG, Leipzig TJ, Kulp RA, Hartzler HE (November 1965). "New sedative and hypotensive 3-substituted 2,4(1H,3H)-quinazolinediones".Journal of Medicinal Chemistry.8 (6):807–815.doi:10.1021/jm00330a017.PMID5885076.
^Havera HJ, Vidrio H (December 1979). "Derivatives of 1,3-disubstituted 2,4(1H,3H)-quinazolinediones as possible peripheral vasodilators or antihypertensive agents".Journal of Medicinal Chemistry.22 (12):1548–1550.doi:10.1021/jm00198a024.PMID231656.
^Garcia JD, Somanathan R, Rivero IA, Aguirre G, Hellberg LH (2000). "Synthesis of Deuterium-Labeled Antihypertensive 3-(4-Phenyl-1′-Piperazinyl)-Propyl-2,4-Quinazolinedione".Synthetic Communications.30 (15):2707–2711.doi:10.1080/00397910008086895.
^Li X, Lee YR, Kim SH (2011). "Concise Synthesis of Pelanserine, Goshuyuamide II, and Wuchuyuamide II with Quinazolinedione Nuclei".Bulletin of the Korean Chemical Society.32 (9):3480–3482.doi:10.5012/bkcs.2011.32.9.3480.
^Cortez R, Rivero IA, Somanathan R, Aguirre G, Ramirez F, Hong E (1991). "Synthesis of Quinazolinedione Using Triphosgene".Synthetic Communications.21 (2):285–292.doi:10.1080/00397919108020823.
^AT 269143B, "Verfahren zur Herstellung von neuen Chinazolindionderivaten und ihrer Säureadditionssalze bzw. ihrer entsprechenden Piperaziniumverbindungen [Process for the preparation of new quinazolinedione derivatives and their acid addition salts or their corresponding piperazinium compounds]", published 1969-03-10, assigned to Miles Laboratories, Inc.
^US 3274194, Shin H, "Quinazolinedione derivatives", issued 20 September 1966, assigned to Bayer Corp.
^US 3919425, Vidrio H, "Method of producing vasodilation using certain 3-substituted-quinazoline derivatives", issued 11 November 1975, assigned to Bayer Corp.
